Volanesorsen for treating familial chylomicronaemia syndrome – guidance (HST13)
Volanesorsen is recommended for genetically confirmed familial chylomicronaemia syndrome in adults at high risk of pancreatitis when response to diet and triglyceride-lowering therapy has been inadequate.
Source:
National Institute for Health and Care Excellence